Ipsen announced Wednesday that CEO David Meek has resigned from his position and will assume the chief executive role at FerGene, a new gene therapy company recently launched by Ferring Pharmaceuticals and Blackstone Life Sciences, effective January 14 next year. Ipsen said that chief medical officer Aymeric Le Chatelier will take over as interim CEO at the start of 2020.

FerGene launched last month with over $570 million in investment to fund the development of the gene therapy nadofaragene firadenovec, also known as rAd-IFN/Syn3, for certain patients with bladder cancer. More recently, the company reported that nadofaragene firadenovec met the primary endpoint of a Phase III study, with over half of patients with high-grade, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) achieving a complete response at three months.

Commenting on his appointment, Meek said "I'm honored to lead FerGene in this exciting role and spearhead the effort to develop and commercialise this critical and innovative therapy." Meek added "I am confident we can efficiently and effectively bring this life changing therapy to patients in need."

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.